Published literature, mechanisms, and protocols, organized by compound. Educational reference, not medical advice.
A sourcing reference for tirzepatide: why its Aib residues and C20 fatty-diacid conjugate shape synthesis, purity analysis, and batch verification. Educational reference.
A trial-by-trial reading of the tirzepatide literature, organized as three research waves: bench pharmacology and cryo-EM structure, the SURPASS diabetes program, and the SURMOUNT weight-management program. Educational reference.
How tirzepatide was engineered as a single-molecule GIP and GLP-1 receptor agonist: its GIP-derived sequence, albumin-binding fatty-acid tail, imbalanced receptor pharmacology, and layered FDA approval history.
A mechanism-focused reading of tirzepatide's peer-reviewed pharmacology: why a single synthetic peptide engages two incretin receptors, how its GLP-1R signaling bias was measured, and what cryo-EM revealed about its binding poses. Educational reference.
A four-movement research-library history of tirzepatide, from the century-old incretin puzzle and the isolation of GIP and GLP-1 through LY3298176's dual-receptor design and a compressed regulatory record. Educational reference.
A sourcing-focused reference on research-grade Thymosin Alpha-1: the acetylation chemistry that defines it, solid-phase synthesis, and the analytical verification recorded on a batch certificate of analysis. Educational reference.
A structured bibliographic survey of the Thymosin Alpha-1 research record, from the 1970s discovery work through chronic-hepatitis randomized trials, TLR-pathway immunomodulation studies, and contemporary immuno-oncology review literature. Educational reference.
A research-library overview of Thymosin Alpha-1 (Tα1 / thymalfasin / Zadaxin): its fraction-5 isolation lineage, acidic 28-residue chemistry and NMR-reported structure, TLR9/dendritic-cell pharmacology, and divergent regulatory footprint. Educational reference.
A mechanism-focused reading of Thymosin Alpha-1: from its acetylated 28-residue sequence and NMR-resolved conformation to the divergent TLR9 (pDC) and TLR2 (mDC) signaling arms, IFNAR/IDO tryptophan catabolism, and the structural questions still open in the literature. Educational reference.
How a partially purified calf-thymus extract named in 1966 became a sequenced 28-residue peptide, a globally approved hepatitis drug, and a 2024 FDA compounding-review subject: the documented history of Thymosin Alpha-1. Educational reference.
A sourcing reference for tesamorelin: how a 44-residue GHRH analogue is assembled by SPPS, why its N-terminal acyl modification demands mass-spectrometric confirmation, and how HPLC and stability data appear on a certificate of analysis. Educational reference.
An annotated tour of the tesamorelin literature organized as two research programs: the pivotal HIV visceral-adiposity trials and the later pivot to hepatic-fat and GH-axis pharmacodynamics. Educational reference.
How a single N-terminal hexenoyl group turned native GHRH(1-44) into tesamorelin: the chemistry, the DPP-IV problem it solves, and the FDA approval record of the first GHRH analog cleared in the US. Educational reference.
A mechanism-focused reading of tesamorelin as a DPP-IV-stabilized GHRH analog: how the trans-3-hexenoic acid cap preserves class B receptor docking, how Gs-cAMP-PKA signaling reaches the GH gene, and why the pituitary feedback loop stays intact. Educational reference.
A timeline of tesamorelin: the 1982 isolation of GHRH from pancreatic tumor tissue, the DPP-IV problem that shaped its hexenoyl chemistry, Theratechnologies' LIPO-010/011 trials, FDA approval of Egrifta in 2010, the EMA divergence, and reformulation through 2025. Educational reference.
Why verifying TB-500 is really a question of confirming a short acetylated fragment (Ac-LKKTETQ), not full-length thymosin beta-4, and how HPLC and mass spectrometry establish that identity. Educational reference.
A structured review of the peer-reviewed literature behind TB-500, tracing the actin-sequestration biochemistry that produced the LKKTETQ fragment, the ophthalmic and cardiac studies conducted on full-length thymosin beta-4, and the analytical work that characterized the fragment itself, with attention to where fragment and parent-protein evidence diverge. Educational reference.
TB-500 is the synthetic, N-acetylated LKKTETQ heptapeptide drawn from the central actin-binding region of thymosin beta-4. This overview traces the fragment's beta-thymosin lineage, its molecular properties, how it is classified, and its regulatory standing. Educational reference.
A mechanism review of TB-500 (Ac-LKKTETQ) as a minimal fragment of thymosin beta-4: how the LKKTETQ WH2 module grips G-actin, why the activity needs no membrane receptor, and how actin buffering links to the cell-migration and NF-kB findings reported in peer-reviewed models. Educational reference.
TB-500's history is a case of mistaken identity: thymosin beta-4 was first characterized as a thymic hormone, then recharacterized as an intracellular actin buffer. This timeline traces that pivot, the mapping of the LKKTETQ fragment, RegeneRx clinical development, and WADA regulatory classification. Educational reference.
An analytical sourcing reference for SS-31 (elamipretide): why its D-amino-acid and dimethyltyrosine residues drive the mass-spectrometry, counter-ion, and stability tests that verify each batch. Educational reference.
Published SS-31 (elamipretide) research traced from its founding inner-membrane biophysics through the cardiolipin hypothesis, mitochondrial interactome mapping, ex vivo human cardiac tissue, and rare-disease clinical programs, with citations to primary literature.
An overview of SS-31 (elamipretide / Bendavia): its aromatic-cationic tetrapeptide design, potential-independent cardiolipin targeting, place among mitochondrial pharmacology classes, and its 2025 FDA accelerated approval. Educational reference.
A sequence-first account of the reported SS-31 (elamipretide) mechanism: why an aromatic-cationic tetrapeptide concentrates at cardiolipin, how it is reported to reverse the cytochrome c peroxidase switch, and what mitochondrial interactome mapping has added. Educational reference.
How SS-31 (elamipretide) traveled from a Cornell opioid-analgesic program to a cardiolipin-targeting mitochondrial compound with a two-decade clinical development record. A sourced research-library timeline.
A sourcing reference for Semax: SPPS of the ACTH(4-10) analog, the two analytical control points that define its purity picture, and what a batch COA documents. Educational reference.
A structured survey of PubMed-indexed Semax research, organized around neurotrophin gene expression, the intact-peptide versus Pro-Gly-Pro metabolite question, monoaminergic microdialysis data, ischemia-model transcriptomics, and copper(II) coordination chemistry.
An overview of Semax as an engineered ACTH(4-10) heptapeptide: how the Pro-Gly-Pro tail and N-terminal copper-binding motif define its chemistry, its melanocortin classification, and its documented Russian registration pathway.
A structure-first review of Semax's reported pharmacology: how the ACTH(4-7) melanocortin core and the appended Pro-Gly-Pro tripeptide relate to neurotrophin induction, monoaminergic effects, and copper coordination documented in primary literature. Educational reference.
How a stabilized ACTH(4-10) fragment became Semax: tracing the peptide from Soviet melanocortin pharmacology and the Myasoedov-Ashmarin collaboration through Russian registration and four decades of shifting research questions.
Why semaglutide's Aib substitution and C18 diacid acyl chain complicate synthesis and analytical identity confirmation, and how batch-level verification addresses it. Educational reference.
A program-by-program bibliographic reference to the semaglutide clinical literature, tracing how the SUSTAIN, PIONEER, STEP, and SELECT trials were designed and what their primary endpoints reported, each attributed to its primary peer-reviewed publication.
A structure-first reference on semaglutide, tracing how fatty-diacid acylation, a DPP-4-resistant Aib substitution, and the SNAC oral-delivery system emerged from three decades of GLP-1 analogue engineering at Novo Nordisk.
A mechanism reference tracing semaglutide from its engineered sequence, DPP-4-resistant Aib-8 substitution and C-18 diacid acylation, through GLP-1 receptor binding, cAMP effector arms, and tissue-level effects reported in peer-reviewed literature.
How semaglutide emerged from four decades of GLP-1 science: the 1980s decoding of the proglucagon gene, the DPP-4 degradation problem that defined the field, the fatty-diacid acylation chemistry that extended plasma half-life toward a once-weekly target, and the sequence of FDA authorizations that followed.
A sourcing-focused look at Selank as a tuftsin-derived heptapeptide: solid-phase synthesis of its proline-rich sequence, the analytical methods that confirm identity and purity, counter-ion considerations, and certificate-of-analysis documentation. Educational reference.
A structured survey of the peer-reviewed Selank literature, from its tuftsin origins through enkephalinase pharmacology, GABAergic gene-expression studies, hippocampal transcriptomics, and the comparative clinical trial behind its Russian registration.
How a Pro-Gly-Pro extension turned the fleeting immunopeptide tuftsin into Selank, a metabolically stabilized heptapeptide studied across GABAergic and enkephalinergic pathways in Russian preclinical and clinical literature.
A mechanism-focused reference tracing Selank from its tuftsin parent peptide through the enkephalin-peptidase, GABAergic-transcription, and BDNF findings reported in Russian and English preclinical literature.
A source-based history of Selank, the tuftsin-derived heptapeptide developed at Moscow's Institute of Molecular Genetics: how a seconds-lived immunopeptide was re-engineered with a Pro-Gly-Pro tail into a compound that reached Russian registration in 2009, and what the literature published before and after that milestone actually reported.
A sourcing reference for retatrutide (LY3437943): its acylated triple-agonist chemistry, why acylation completeness is the analytically demanding step, and the HPLC, mass-spectrometry, and batch-COA verification that supports research reproducibility. Educational reference.
A bibliographic summary of the primary peer-reviewed literature on retatrutide (LY3437943), tracing the compound from its founding discovery paper through cryo-EM structural biology and its phase 1 and phase 2 clinical trial program. Educational reference.
Retatrutide (LY3437943) is a synthetic acylated peptide engineered as a single-molecule agonist at three metabolic receptors. This reference profiles its GIP-derived scaffold, unbalanced triple-receptor potency, and place in the incretin-peptide development timeline.
A mechanism-focused review of retatrutide (LY3437943): its deliberately unbalanced potency across the GIP, GLP-1, and glucagon receptors, the Gs-adenylyl cyclase-cAMP signaling shared by all three class B GPCRs, and the cryo-EM structural basis of triple engagement. Educational reference.
Retatrutide (LY3437943) traced through the discovery timelines of its three parent hormones — glucagon, GIP, and GLP-1 — the unimolecular co-agonist chemistry that unified them, and its clinical development record. Educational reference.
A sourcing reference for PT-141 (bremelanotide): why its cyclic lactam architecture and MT-II lineage shape analytical verification, and what a batch COA documents. Educational reference.
A research-library summary of the published bremelanotide (PT-141) literature, organized by its melanotan II lineage, the intranasal male-population trials, and the subcutaneous RECONNECT phase 3 program that supported FDA approval. Educational reference.
From a melanotan-II side product to the first approved melanocortin agonist: an educational reference on PT-141 (bremelanotide) chemistry, MC4R pharmacology, and its regulatory record.
A mechanism-focused reference on bremelanotide (PT-141): its origin as a Melanotan-II metabolite, the alpha-MSH message sequence, MC3R/MC4R agonism, and hypothalamic Gs/cAMP signaling. Educational reference.
How a University of Arizona sunless-tanning peptide program produced bremelanotide (PT-141): the MT-II lineage, the redirecting observation of central effects, the intranasal-to-subcutaneous pivot, RECONNECT trials, and 2019 Vyleesi approval.
